Halozyme Therapeutics, Inc. (NASDAQ:HALO) Position Increased by Tower Research Capital LLC TRC

Tower Research Capital LLC TRC raised its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 388.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 20,126 shares of the biopharmaceutical company's stock after buying an additional 16,002 shares during the period. Tower Research Capital LLC TRC's holdings in Halozyme Therapeutics were worth $962,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in HALO. Mesirow Institutional Investment Management Inc. lifted its holdings in shares of Halozyme Therapeutics by 37.6% in the fourth quarter. Mesirow Institutional Investment Management Inc. now owns 302,148 shares of the biopharmaceutical company's stock valued at $14,446,000 after purchasing an additional 82,643 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in Halozyme Therapeutics by 7.8% during the 4th quarter. MetLife Investment Management LLC now owns 145,265 shares of the biopharmaceutical company's stock worth $6,945,000 after acquiring an additional 10,538 shares during the last quarter. BI Asset Management Fondsmaeglerselskab A S lifted its position in shares of Halozyme Therapeutics by 45.1% during the fourth quarter. BI Asset Management Fondsmaeglerselskab A S now owns 427,207 shares of the biopharmaceutical company's stock valued at $20,425,000 after purchasing an additional 132,795 shares in the last quarter. Capital World Investors purchased a new position in Halozyme Therapeutics during the fourth quarter worth about $35,773,000. Finally, Dimensional Fund Advisors LP grew its position in Halozyme Therapeutics by 2.5% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,933,560 shares of the biopharmaceutical company's stock worth $92,446,000 after purchasing an additional 47,795 shares in the last quarter. Institutional investors own 97.79% of the company's stock.

Analysts Set New Price Targets

Several equities analysts recently commented on the company. Benchmark reiterated a "buy" rating and issued a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Wells Fargo & Company cut their price target on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Piper Sandler upped their price objective on shares of Halozyme Therapeutics from $52.00 to $53.00 and gave the company a "neutral" rating in a report on Friday, January 10th. JPMorgan Chase & Co. increased their target price on shares of Halozyme Therapeutics from $55.00 to $58.00 and gave the stock a "neutral" rating in a research report on Monday, April 21st. Finally, HC Wainwright reissued a "buy" rating and issued a $72.00 price target on shares of Halozyme Therapeutics in a research report on Friday, April 25th. Four analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $62.89.

Insider Transactions at Halozyme Therapeutics

In other news, Director Jeffrey William Henderson sold 5,000 shares of Halozyme Therapeutics stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $56.30, for a total transaction of $281,500.00. Following the sale, the director now owns 38,611 shares in the company, valued at approximately $2,173,799.30. The trade was a 11.46 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Michael J. Labarre sold 1,697 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the transaction, the senior vice president now directly owns 173,756 shares of the company's stock, valued at approximately $10,126,499.68. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 26,697 shares of company stock valued at $1,558,052. 2.40% of the stock is currently owned by corporate insiders.

Halozyme Therapeutics Stock Performance

HALO stock traded down $0.59 during trading on Thursday, hitting $60.83. 247,136 shares of the company traded hands, compared to its average volume of 1,435,470. The company has a market cap of $7.51 billion, a PE ratio of 17.77, a P/E/G ratio of 0.42 and a beta of 1.32. Halozyme Therapeutics, Inc. has a 1 year low of $38.30 and a 1 year high of $66.00. The stock's 50-day simple moving average is $60.70 and its 200 day simple moving average is $55.28. The company has a debt-to-equity ratio of 4.14, a current ratio of 7.80 and a quick ratio of 9.15.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings results on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.17 by $0.02. The business had revenue of $298.01 million during the quarter, compared to analyst estimates of $285.74 million. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. On average, equities analysts expect that Halozyme Therapeutics, Inc. will post 4.73 earnings per share for the current fiscal year.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.